Usher Syndrome - Pipeline Review, H1 2018

  • ID: 4576056
  • Report
  • 41 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Editas Medicine Inc
  • Ionis Pharmaceuticals Inc
  • ProQR Therapeutics NV
  • Sanofi
  • MORE
Usher Syndrome - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome - Pipeline Review, H1 2018, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.

Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.

Report Highlights:

This latest pipeline guide Usher Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Usher Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Usher Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Editas Medicine Inc
  • Ionis Pharmaceuticals Inc
  • ProQR Therapeutics NV
  • Sanofi
  • MORE
Introduction

Report Coverage

Usher Syndrome - Overview

Usher Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Usher Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Usher Syndrome - Companies Involved in Therapeutics Development

Amgen Inc

Editas Medicine Inc

Ionis Pharmaceuticals Inc

ProQR Therapeutics NV

Sanofi

Usher Syndrome - Drug Profiles

ASO-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BF-844 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate CLRN1 for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate MYO7A for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-421 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-421869 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Usher Syndrome - Dormant Projects

Usher Syndrome - Product Development Milestones

Featured News & Press Releases

Sep 05, 2017: ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

Jul 05, 2017: ProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

May 01, 2017: ProQR to Present Data on QRX-411 at ARVO

May 01, 2017: ProQR to Present Data on QRX-421 at ARVO

Sep 18, 2012: Neurotech Pharmaceuticals Provides Update On NT-501

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Usher Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Usher Syndrome - Pipeline by Amgen Inc, H1 2018

Usher Syndrome - Pipeline by Editas Medicine Inc, H1 2018

Usher Syndrome - Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Usher Syndrome - Pipeline by ProQR Therapeutics NV, H1 2018

Usher Syndrome - Pipeline by Sanofi, H1 2018

Usher Syndrome - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Usher Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen Inc
  • Editas Medicine Inc
  • Ionis Pharmaceuticals Inc
  • ProQR Therapeutics NV
  • Sanofi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll